October 27, 2020

FLM Online Subscription | Leaderboard | 600×75
JinkoSolar confirmed as most bankable PV module supplier for five-year period 2015-2020
article image

SHANGHAI, June 10, 2020 /PRNewswire/ — JinkoSolar has been confirmed as the most bankable photovoltaic (PV) module supplier to the solar industry for the five year period covering 2015 to 2020, according to the second quarter (Q2) 2020 release of the PV ModuleTech Bankability Ratings Quarterly report, compiled and released by leading third-party market researchers at PV-Tech.org.

PV-Tech’s unique rating system for the PV industry is now seen as the gold standard for utility-scale site developers, investors and owners, in assessing the most bankable PV module suppliers for site selection. The PV ModuleTech Bankability Ratings analysis ranks PV module suppliers by manufacturing and financial health, yielding an overall bankability rating from zero to 10.

During the five year period from 2015 to 2020, JinkoSolar is the only PV module supplier to average above 7 in the 0-10 rating system, firmly at the upper end of the AA-Rating band. JinkoSolar’s bankability rating is also 67% above the average of the leading peer group of module suppliers (top-15-20) that have featured in the A and B grades during the past five years.

JinkoSolar Bankability Score

According to the Q2 2020 release of PV-Tech’s PV ModuleTech Bankability Ratings Quarterly report: “JinkoSolar continues to set the benchmark as a pure-play multi-GW module supplier, by increasing shipments Y/Y while keeping operating margins positive”. The analysis of JinkoSolar in the report also comments on the company’s successful module supply strategy, with the consistently high ratings being “a clear sign of a strong and stable (and effective) business plan working, and one that can adapt to any regional end-market shocks”.

Read more

< Previous

The Third Consecutive Year of Tongwei Group Donating Off-grid Photovoltaic Power Generation Systems to Uninhabited Areas in Qinghai and Tibet

ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities